Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
P30 CA008748
NCI NIH HHS - United States
PubMed
35736670
PubMed Central
PMC9636322
DOI
10.1182/bloodadvances.2022007812
PII: 485664
Knihovny.cz E-zdroje
- MeSH
- bicyklické sloučeniny heterocyklické terapeutické užití MeSH
- chronická lymfatická leukemie * farmakoterapie MeSH
- lidé MeSH
- opakovaná terapie MeSH
- sulfonamidy terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- bicyklické sloučeniny heterocyklické MeSH
- sulfonamidy MeSH
- venetoclax MeSH Prohlížeč
Amsterdam University Medical Centers Amsterdam The Netherlands; and
Colchester General Hospital East Suffolk and North Essex NHS Foundation Trust Essex United Kingdom
Dartmouth Hitchcock Medical Center Lebanon NH
Department of Medicine Memorial Sloan Kettering Cancer Center New York NY
Genentech Inc South San Francisco CA
Hackensack University Medical Center Hackensack NJ
Northwell Health Cancer Institute Lake Success NY
Oxford University Hospitals NHS Foundation Trust Oxford United Kingdom
Riverside Regional Medical Center Newport News VA
Roche Products Ltd Welwyn Garden City United Kingdom
Royal Hobart Hospital Tasmania Australia
University Hospital Hradec Kralove Charles University Hradec Kralove Czech Republic
University of Arizona Cancer Center Tuscon AZ
University of California San Diego San Diego CA
University of Colorado Cancer Center Denver CO
University of North Carolina Chapel Hill NC
University of Pennsylvania Philadelphia PA
Weill Cornell Medicine New York NY
Wilmot Cancer Institute University of Rochester Medical Center Rochester NY
Zobrazit více v PubMed
Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322. PubMed PMC
Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120. PubMed
Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. PubMed
Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–1200. PubMed
Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269–277. PubMed
Ma S, Seymour JF, Brander DM, et al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. Blood. 2021;138(10):836–846. PubMed PMC
Harrup RA, Owen C, D'Rozario J, et al. Efficacy of subsequent novel targeted therapies, including repeated venetoclax-rituximab (VenR), in patients (Pts) with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) previously treated with fixed-duration Venr in the Murano Study [abstract] Blood. 2020;136:44–45. suppl 1.
Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. PubMed
StataCorp. 2021 Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021.
Mato AR, Davids MS, Sharman J, et al. Recognizing unmet need in the era of targeted therapy for CLL/SLL: “what's past is prologue” (Shakespeare) Clin Cancer Res. 2022 28(4):603-608. PubMed PMC
Lew TE, Lin VS, Cliff ER, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5(20):4054–4058. PubMed PMC
Mato AR, Roeker LE, Jacobs R, et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res. 2020;26(14):3589–3596. PubMed PMC
Thompson MC, Roeker LE, Coombs CC, et al. Addressing a new challenge in chronic lymphocytic leukemia: outcomes of therapies after exposure to both a covalent Bruton's tyrosine kinase inhibitor and venetoclax [abstract] Blood. 2021;138:2628. suppl 1.
Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021;138(5):361–369. PubMed
